New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2013
14:32 EDTZGNXZogenix surges after FDA approves pain management drug
Shares of Zogenix (ZGNX) are jumping after the company announced that the FDA had approved its pain management drug. WHAT'S NEW: The FDA announced intraday that it approved Zogenix's pain management drug, Zohydro. The agency approved the drug for use by patients who have pain severe enough to require daily, around-the-clock, long-term treatment and who cannot be adequately comforted with other treatment options, the company stated. WHAT'S NOTABLE: In a note to investors on September 27, William Blair analyst Tim Lugo wrote that his price target for Zogenix would have been about $6 if the FDA was to approve Zohydro. According to Lugo, Zogenix had several upcoming catalysts other than Zohydro that could enable the stock to outperform through September 2014. He kept an Outperform rating on the shares. TODAY'S PRICE ACTION: In mid-afternoon trading, Zogenix surged 93c, or 40%, to $3.15.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
18:58 EDTZGNXOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTZGNXZogenix confirms reversal of Zohydro sales ban in Massachusetts
Subscribe for More Information
15:33 EDTZGNXZogenix wins reversal of Zohydro sales ban in Mass., Boston Globe says
A federal judge ruled that Massachusetts cannot block sales of Zogenix's Zohydro in the state, as had been previously ordered by Governor Deval Patrick, reports The Boston Globe. Reference Link
14:33 EDTZGNXJudge strikes down ban on Zogenix's Zohydro, Boston Globe says
Subscribe for More Information
April 9, 2014
09:11 EDTZGNXOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTZGNXZogenix rises 8.9%
Zogenix is up 8.9%, or 23c, to $2.82
05:16 EDTZGNXZogenix requested order staying the ban of Zohydro in MA
Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the FDA-approved prescription drug product, Zohydro ER extended-release capsules, entered on March 27, by Massachusetts Governor Deval Patrick. A follow-up hearing has been scheduled for Monday, April 14. The company will continue to monitor, evaluate and take appropriate actions in all states specific to Zohydro ER to ensure that all FDA-approved Schedule II prescription opioids covered by the FDA mandated Risk Evaluation Mitigation Strategy for extended-release and long-acting opioid analgesics receive equal treatment for any rules that impact patient access and prescribing.
April 7, 2014
16:15 EDTZGNXZogenix files suit against Massachusetts to block ban of Zohydro ER
Subscribe for More Information
April 2, 2014
21:53 EDTZGNXZogenix says 'extremely disappointed' in DEA's 'misinformation'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use